Long-term follow-up for A2 Bio gene therapy patients
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received at least one dose of an A2 Bio gene therapy product in a previous A2 Bio study.
- You must be willing and able to sign a consent form for this follow-up study.
- You must be able to follow the study's instructions and schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people who have already received a cell or gene therapy in another AstraZeneca study. It simply checks in on your health over time after that treatment.
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
This study checks how people do over the long term after receiving CAR-T, an advanced immune treatment. It may help doctors understand long-term safety and benefits, and what to expect after treatment.
This study follows people for many years after they receive gene therapy (a treatment that uses lab-made genetic material). It mainly checks long-term safety and health outcomes and may help doctors understand how gene therapy works over time.
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.